Recognizing publication bias, a meta-analysis of 29 studies (n=6129) indicates administering immune checkpoint inhibitors earlier in the day—typically before mid-afternoon—was consistently associated with improved overall and progression-free survival across cancer types, supporting both the emerging concept of immuno- “chronotherapy” as well as humane clinic hours. | Inoue, JAMA Netw Open 2026
